EPIX
Income statement / Annual
Last year (2024), ESSA Pharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, ESSA Pharma Inc.'s net income was -$28.54 M.
See ESSA Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$217.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$118.49 K
|
$121.79 K
|
$109.46 K
|
$110.32 K
|
$0.00
|
$34.49 K
|
$46.15 K
|
$66.18 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$118.49 K
|
-$121.79 K
|
-$109.46 K
|
-$110.32 K
|
$0.00
|
-$34.49 K
|
-$46.15 K
|
-$65.96 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-303.98
|
0
|
| Research and Development Expenses |
$21.21 M
|
$21.32 M
|
$24.42 M
|
$24.26 M
|
$12.15 M
|
$6.70 M
|
$4.87 M
|
$5.73 M
|
$13.06 M
|
$4.39 M
|
| General & Administrative Expenses |
$0.00
|
$10.79 M
|
$12.55 M
|
$12.78 M
|
$11.37 M
|
$5.47 M
|
$5.93 M
|
$5.14 M
|
$5.64 M
|
$3.70 M
|
| Selling & Marketing Expenses |
$0.00
|
$22.57 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$10.81 M
|
$12.55 M
|
$12.78 M
|
$11.37 M
|
$5.47 M
|
$5.93 M
|
$5.14 M
|
$5.64 M
|
$3.70 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.74 M
|
$109.46 K
|
$515.00 K
|
$35.00 K
|
-$40.00 K
|
-$37.00 K
|
$79.00 K
|
$1.15 M
|
| Operating Expenses |
$21.21 M
|
$32.13 M
|
$36.96 M
|
$37.14 M
|
$23.52 M
|
$12.17 M
|
$10.80 M
|
$10.87 M
|
$18.70 M
|
$9.23 M
|
| Cost And Expenses |
$0.00
|
$32.13 M
|
$36.96 M
|
$37.14 M
|
$23.52 M
|
$12.17 M
|
$10.80 M
|
$10.87 M
|
$18.70 M
|
$9.23 M
|
| Interest Income |
$0.00
|
$5.55 M
|
$1.74 M
|
$235.00 K
|
$559.72 K
|
$26.25 K
|
$42.73 K
|
$0.00
|
$0.00
|
$618.25
|
| Interest Expense |
$0.00
|
$6.94 K
|
$14.00 K
|
$22.22 K
|
$618.00 K
|
$603.00 K
|
$912.00 K
|
$785.00 K
|
$938.00 K
|
$77.77 K
|
| Depreciation & Amortization |
$0.00
|
$118.49 K
|
$121.79 K
|
$109.46 K
|
$110.32 K
|
$18.30 K
|
$34.49 K
|
$46.15 K
|
$66.18 K
|
$39.10 K
|
| EBITDA |
-$28.45 M |
-$26.46 M |
-$35.08 M |
-$36.71 M |
-$23.01 M |
-$12.13 M |
-$10.77 M |
-$3.55 M |
-$18.67 M |
-$9.38 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-86017.88
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-90516.13
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
$5.55 M
|
$1.74 M
|
$303.76 K
|
-$214.10 K
|
-$567.49 K
|
-$552.91 K
|
$11.68 M
|
$5.74 M
|
-$107.36 K
|
| Income Before Tax |
-$28.54 M
|
-$26.58 M
|
-$35.22 M
|
-$36.84 M
|
-$23.73 M
|
-$10.40 M
|
-$11.60 M
|
-$4.38 M
|
-$12.99 M
|
-$8.57 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-59857.14
|
0
|
| Income Tax Expense |
$0.00
|
$1.60 K
|
-$112.00 K
|
-$34.35 K
|
-$289.00 K
|
$38.00 K
|
$27.00 K
|
$116.00 K
|
$151.00 K
|
$77.77 K
|
| Net Income |
-$28.54 M
|
-$26.58 M
|
-$35.10 M
|
-$36.81 M
|
-$23.45 M
|
-$10.44 M
|
-$11.63 M
|
-$4.50 M
|
-$13.14 M
|
-$8.57 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-60553
|
0
|
| EPS |
-0.64 |
-0.6 |
-0.8 |
-0.96 |
-1.04 |
-1.24 |
-2.55 |
-3.09 |
-9.77 |
-9.34 |
| EPS Diluted |
-0.64 |
-0.6 |
-0.8 |
-0.96 |
-1.04 |
-1.24 |
-2.55 |
-3.09 |
-9.77 |
-9.34 |
| Weighted Average Shares Out |
$44.28 M
|
$44.09 M
|
$44.04 M
|
$38.48 M
|
$22.44 M
|
$8.43 M
|
$4.57 M
|
$1.45 M
|
$1.35 M
|
$917.65 K
|
| Weighted Average Shares Out Diluted |
$44.28 M
|
$44.09 M
|
$44.04 M
|
$38.48 M
|
$22.44 M
|
$8.43 M
|
$4.57 M
|
$1.45 M
|
$1.35 M
|
$917.65 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
